logo
  Join        Login             Stock Quote

SXC HEALTH SOLUTIONS TO ACQUIRE MEDFUSIONRX, LLC

Thursday, December 2, 2010 7:01 AM


- Acquisition strengthens SXC's presence in specialty pharmacy -
- Transaction expected to be immediately accretive to earnings per share -

LISLE, Il -SXC Health Solutions Corp. ("SXC" or the "Company")
(NASDAQ: SXCI, TSX: SXC), a leading provider of pharmacy benefit management (PBM)
services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry, announces that it has entered into a definitive agreement to acquire MedfusionRx, LLC ("MedfusionRx") for a purchase price of $100 million in cash, subject to certain customary post-closing adjustments, with an additional $5.5 million subject to the achievement of certain performance targets through the 2012 fiscal year.

MedfusionRx is a leading privately-owned specialty pharmacy provider with significant expertise in providing clinical services to over 9,000 patients with complex chronic conditions.

"Specialty pharmaceuticals are the fastest growing area in the PBM space and our clients recognize it as the next critical area of drug spend management. This acquisition will expand our presence and enhance our capabilities in the specialty pharmacy market which differentiates us from our peers in the mid-market PBM sector," said Mark Thierer, President and CEO of SXC. "Acquiring MedfusionRx increases the size of our specialty operations to approximately $400 million and allows us to better assist our clients and their members in managing complex conditions, such as cancer, with the most supportive and cost-effective care.  The MedfusionRx management team adds proven specialty industry experience to our Ascend team and further expands the scale of our platform to capitalize on the opportunity in this rapidly growing segment of the PBM industry."

MedfusionRx manages approximately $270 million of drug spend annually and has approximately $11.5 million in trailing twelve month adjusted EBITDA. In addition, SXC has identified approximately $4-6 million of cost saving synergies, including the tax benefits of the acquisition, expected to be realized within 18-24 months of the closing of the transaction. The acquisition is expected to be $0.08 to $0.10 accretive to SXC's GAAP earnings per share ("EPS") in 2011. Excluding an estimated $7 million in deal-related amortization (or $0.07 per share), the acquisition is expected to generate $0.15 to $0.17 in adjusted EPS in 2011.

"SXC has emerged as a leader in the PBM market for technology innovation and flexible client-focused solutions. Our skill and experience in specialty pharmaceuticals will help enhance the great work SXC has already done to transform how pharmacy benefits are delivered. Our clients, as well as our employees, will benefit greatly from SXC's operational and financial resources, and we believe that our client-service culture will merge well with SXC's current specialty offering," said Jeff Vernon, President of MedfusionRx.

Mr. Thierer continued, "MedfusionRx has a talented team that has expanded its reach into all 50 states. Importantly, MedfusionRx provides services to more than 30 state clients and manages thousands of state Medicaid patients, creating some compelling revenue synergy opportunities for SXC. We are excited with the growth prospects inherent in this transaction and will continue to explore other opportunities to expand our business through acquisitions."

MedfusionRx is based in Birmingham, Alabama, where its operations will remain. Following the closing of the transaction, SXC plans to maintain the MedfusionRx brand. MedfusionRx specializes in the needs of patients across a variety of disease indications including: bleeding disorders, such as hemophilia; growth hormone deficiency; multiple sclerosis; rheumatoid arthritis; plaque psoriasis; Crohn's disease; hepatitis C; oncology; and preventative treatment of respiratory syncytial virus.

The acquisition is subject to various closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to be completed by the end of 2010. 

In connection with the transaction, Healthcare Growth Partners, LLC is acting as financial advisor and Sidley Austin LLP is acting as legal counsel to SXC.


Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.